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results. Similarly, we observed no differences between
heparin-plasma and serum samples analyzed on the
Vitros system. The layered slide technology on the Vitros
prevents precipitation penetrating through to the reaction
layer. When we measured glucose, we observed no dif-
ferences between the heparin-plasma or serum samples
with the Rapidlab 865. The membrane on the glucose
sensor also prevents precipitation from potentially caus-
ing reaction problems.
In conclusion, 2 samples with IgM- paraproteins pro-
duced interference with the Roche glucose and GGT
methods when collected as lithium heparin–plasma sam-
ples. Automatic reruns gave the same error flags. The best
way to obtain accurate glucose and GGT results for these
patients was to use a serum sample or a different mea-
surement system for glucose analysis.
We thank Barbara Mottram (Mater Laboratories Services,
Brisbane, Australia) for assaying the samples on their
Vitros 950 analytical system and Dr. Graham Jones (St
Vincent’s Hospital, Sydney, Australia) for reviewing the
manuscript.
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Hepatic glucuronization of water-insoluble bilirubin is
catalyzed by isoenzyme 1A1 of UDP-glucuronosyltrans-
ferase (UGT1A1), which is essential for efficient biliary
excretion of bilirubin. Mild hyperbilirubinemia, usually
50 mol/L, is associated with Gilbert syndrome (GS)
and is thought to reflect a small reduction in UGT1A1
activity (1, 2). The main cause of GS in all studied
populations is a TA insertion in the repetitive TATA box
of the gene promoter (3–6), which usually consists of 6
repeats. This (TA)7 allele is extremely common, occurring
with an estimated frequency of 38.7% in the white popu-
lation and 16% in the Asian population (7 ). In persons
with African ancestry, the number of alleles carrying 7 or
more repeats is reported to be 49.5% (7 ). On the basis of
the frequencies observed in Caucasians in several studies
of smaller series, Beutler et al. (7 ) calculated a homozy-
gosity frequency of 15%. This predicted value is higher
than that in patients with a clinical diagnosis of GS,
suggesting incomplete penetrance of the (TA)7 allele.
Moreover, the fact that some GS patients are neither
homozygous for the (TA)7 allele nor have other UGT1A1
genetic deficits points toward the existence of other inher-
ited or acquired factors affecting bilirubin metabolism.
Phenobarbital treatment for hyperbilirubinemia in-
creases UGT1A1 activity in the liver via a phenobarbital-
responsive enhancer sequence with 3 potential nuclear
receptor (NR) motifs separated by90 bases (8 ). From the
5end, these motifs are named NR4, gtNR1, and NR3.
Alterations in this region could be related to hyperbiliru-
binemia (8 ). A polymorphism (c.-3279TG) located in the
NR3 motif is associated with a decrease in transcriptional
activity, to 62% of wild type (9 ). This polymorphism
was found in patients with GS and the (TA)7 allele (9, 10).
More recently, a similar cooperative effect has been ob-
served in cancer patients showing severe irinotecan tox-
icity (11 ).
The aim of the present study was to screen for the
presence of alterations in the phenobarbital-responsive
enhancer sequence of the UGT1A1 gene and to investigate
a possible association of these alterations with GS.
We studied 80 unrelated Caucasian patients (53 males
and 37 females) 14 to 45 years of age. The diagnosis of GS
was based on standard criteria of mild unconjugated
hyperbilirubinemia, normal liver function tests, and no
overt signs of hemolysis. The mean (SD) total bilirubin
concentration was 29.2 (10.07) mol/L. Sixty-seven pa-
tients were homozygous for the (TA)7 allele in the pro-
moter region of the UGT1A1 gene, and 13 were heterozy-
gous. Direct sequencing of the 5 exons and promoter
region (c.-1568 to c.-1043) in these (TA)7 heterozygotes
revealed no additional alterations. We also studied 75
Caucasian individuals with no known history of jaundice
(control group).
In all 80 GS patients, the phenobarbital-responsive
enhancer sequence of the UGT1A1 gene (c.-3576 to
c.-3209) was sequenced using the primers UGT1A1regF
(5-CTAGCCATTCTGGATCCCTTG-3) and UGT1A1regR
(5-TTTTGAGATCTGAGTTCTCTTCACCTC-3). PCR was
performed in a 50-L volume containing 25 L of PCR
Master Mix (Promega), 22 L of water, 1 L of each
primer (50 pmol/L), and 1 L (250 ng) of genomic DNA.
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Amplification was performed in a GeneAmp PCR System
9600 thermal cycler (Applied Biosystems) with an initial
denaturation step of 95 °C for 10 min, followed by 35
cycles of 95 °C for 1 min, 55 °C for 1 min, and 72 °C for 1
min, with a final extension at 72 °C for 10 min. The
amplicons were isolated by electrophoresis on a 2%
agarose gel and then purified by use of the spin-X®
(Corning Incorporated). The nucleotide sequence was
determined, with use of the respective forward and
reverse primers, in independent sequencing reactions
with the Dye Terminator Cycle Sequencing Kit (Perkin-
Elmer) and subsequently resolved on an ABI Prism 310
Genetic Analyzer (Applied Biosystems).
In the control group, single-strand conformational analy-
sis was performed for carrier detection of the c.-3279TG
polymorphism within the phenobarbital-responsive en-
hancer sequence. Amplicons were electrophoresed at
room temperature on 0.5	MDE gels (BMA Products) and
visualized by conventional silver staining methods.
The control group was also screened for the (TA)7 allele
in the promoter region of the UGT1A1 gene. This TATA
box region was analyzed by PCR amplification using the
primers described by Bancroft et al. (12 ), with the intro-
duction a fluorochrome label in the reverse primer for
subsequent analysis by automated capillary electrophore-
sis. PCR was performed in a 50-L volume containing 25
L of PCR Master Mix (Promega), 22 L of water, 1 L of
each primer (50 pmol/L), and 1 L (250 ng) of genomic
DNA. PCR amplification was performed in a GeneAmp
PCR System 9600 thermal cycler with an initial denatur-
ation step of 95 °C for 10 min, followed by 35 cycles of
95 °C for 1 min, 60 °C for 1 min, and 72 °C for 1 min, with
final extension at 72 °C for 30 min. After PCR, 1-L
portions of the products were separated by automated
capillary electrophoresis and analyzed by GeneScan (Ver.
3) software (Applied Biosystems), along with the molec-
ular weight marker ROXTM–500 size standard (Applied
Biosystems).
Direct sequencing of the phenobarbital-responsive en-
hancer sequence in the GS patients revealed only the
presence of the c.-3279TG polymorphism, which was
found in homozygosity in 74 (92.5%) and heterozygosity
in 6 (7.5%) of the patients (Table 1). The frequency of this
polymorphism was significantly higher in the GS group
than in the control group (96.25% vs 41.33%; 
2  110.5; P
0.001). The great majority of GS patients and control
group members homozygous for the (TA)7 allele were
also homozygous for the c.-3279TG polymorphism
(95.83%). In individuals heterozygous for the (TA)7 allele,
the presence of homozygosity for the c.-3279TG poly-
morphism was significantly higher in the GS group (69%)
than in the control group (28%; 
2  6.461; P  0.011).
In the control group, we found a compound heterozy-
gote for the (TA)5 and (TA)7 alleles associated with
homozygosity for the c.-3279TG polymorphism.
We found no statistically significant difference among
bilirubin concentrations in the different patient hapto-
types. This analysis, however, was limited by fewer
numbers of cases in 3 of the 4 genotype combinations.
Further comparisons and statistical analyses were also
inhibited because no bilirubin concentrations were known
for the anonymized control group.
Homozygosity for the (TA)7 allele was initially consid-
ered to be the sole cause of GS in Caucasians (3–6);
however, it has become increasingly evident that the
genotype/phenotype relationship is not linear
(6, 7, 10, 13). On the one hand, the bilirubin concentra-
tions in such patients are very heterogeneous, whereas on
the other hand, some people without GS are also found to
be homozygous for this allele. For this reason, many
authors search for other factors that could influence
phenotypic expression.
In the present study, the c.-3279TG polymorphism
was a common finding in both GS and control individu-
als. Its much higher frequency in the GS group suggests,
however, that it may be a significant contributor.
The (TA)7 allele decreases the transcriptional activity of
the UGT1A1 gene to only 60%–80% of normal (4, 7), and
the c.-3279TG polymorphism decreases it to 62% of
normal (9 ). The association of these 2 variants could thus
lower the transcriptional activity of the UGT1A1 gene to
as little to as 37% of normal. Almost all of our GS patients
who were homozygous for the (TA)7 allele were also
homozygous for the c.-3279TG polymorphism, suggest-
Table 1. Distribution of the c.-3279T>G polymorphism and (TA)7 insertion in control and GS groups.
Group TATA box [A(TA)7TAA]
c.-3279T>G
Wild type Heterozygous Homozygous
GS patients (n  80) Wild type (n  0), n 0 0 0
Heterozygous (n  13)
n 0 4 9
Mean (SD) bilirubin, mol/L 35 (13.89) 23.72 (6.88)
Homozygous (n  67)
n 0 2 65
Mean (SD) bilirubin, mol/L 28.4 (11.17) 26.7 (6.88)
Controls (n  75)a Wild type (n  40), n 24 15 1
Heterozygous (n  29), n 3 18 8
Homozygous (n  5), n 0 1 4
a One patient was heterozygous for the (TA)5 and (TA)7 alleles.
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ing a linkage between these 2 markers. Indeed, linkage
dysequilibrium between these 2 markers was recently
demonstrated in a group of 133 healthy Caucasian indi-
viduals (14 ).
We also found homozygosity for the c.-3279TG poly-
morphism in a large number (70%) of our GS patients
who were heterozygous for the (TA)7 allele. This geno-
type could be sufficient to justify the clinical picture found
in these patients, as could compound heterozygosity for
(TA)7 and c.-3279TG.
In summary, these results suggest that the c.-3279TG
polymorphism of the UGT1A1 gene could be an addi-
tional, if only cumulative, risk factor for the development
of GS, thus justifying the inclusion of this polymorphism
in routine molecular screening protocols.
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